Transient MEK inhibitor-associated retinopathy in metastatic melanoma

Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).

(2017) Richard D. Carvajal et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date

(2013) Charlotte Lemech et al.   DRUGS

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

(2013) Paolo A Ascierto et al.   LANCET ONCOLOGY

RASopathic Skin Eruptions during Vemurafenib Therapy

(2013) Jeannine D. Rinderknecht et al.   PLoS One

Treatment of cystic macular lesions in hereditary retinal dystrophies

(2013) Serena Salvatore et al.   SURVEY OF OPHTHALMOLOGY

Resistance patterns with tyrosine kinase inhibitors in melanoma

(2012) Reinhard Dummer et al.   CURRENT OPINION IN ONCOLOGY

Topical dorzolamide therapy for taxane-related macular oedema

(2012) J P Ehlers et al.   EYE

Ocular Toxicity of Targeted Therapies

(2012) Daniel J. Renouf et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

(2012) Jeffrey R Infante et al.   LANCET ONCOLOGY

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

The mystery of angiographically silent macular oedema due to taxanes

(2012) Tatiana I. Kuznetcova et al.   INTERNATIONAL OPHTHALMOLOGY

Angiographically silent cystoid macular oedema secondary to paclitaxel therapy

(2011) Constantine D Georgakopoulos et al.   Clinical and Experimental Optometry

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin

(2011) David C. Whiteman et al.   Pigment Cell & Melanoma Research

Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders

(2010) K. Schad et al.   CLINICAL CANCER RESEARCH

Blood-Retinal Barrier

(2010) José Cunha-Vaz et al.   EUROPEAN JOURNAL OF OPHTHALMOLOGY

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

(2010) Christophe Frémin et al.   Journal of Hematology & Oncology

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nonsteroidal Anti-inflammatory Drugs in Ophthalmology

(2010) Stephen J. Kim et al.   SURVEY OF OPHTHALMOLOGY

PD0325901, a Mitogen-Activated Protein Kinase Kinase Inhibitor, Produces Ocular Toxicity in a Rabbit Animal Model of Retinal Vein Occlusion

(2009) Wenhu Huang et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Etiology and Treatment of Macular Edema

(2008) Mark W. Johnson   AMERICAN JOURNAL OF OPHTHALMOLOGY

Central serous chorioretinopathy

(2007) Maria Wang et al.   ACTA OPHTHALMOLOGICA